1st Optimal Pricing History and Trajectory: An Independent Review

What Is 1st Optimal and How Does Its Business Model Work?

1st Optimal positions itself as a performance and longevity medicine practice operating on a cash-pay concierge model. Patients pay out of pocket for physician consultations, laboratory panels, and compounded or branded medications. No insurance billing is offered, which removes prior-authorization delays but transfers full cost to the patient.

Cash-Pay Concierge: What You Actually Buy

In a standard concierge arrangement, the monthly or quarterly fee typically covers provider access, protocol adjustments, and follow-up messaging. Medications are billed separately. This fee structure is common across the direct-to-consumer TRT market, where brands like Defy Medical, Marek Health, and Hone Health use comparable bundling strategies.

The FDA regulates all prescription drugs dispensed through such platforms, including compounded testosterone cypionate and peptides like sermorelin or ipamorelin. The agency's guidance on compounding is published under 21 U.S.C. § 353b and enforced through its compounding compliance program. [1]

Why Cash-Pay Pricing Is Hard to Pin Down

Prices at cash-pay clinics change without the regulatory filing requirements that apply to insured products. 1st Optimal does not publish a full fee schedule publicly, which is consistent with competitor practice but makes independent price verification difficult. The analysis below draws on archived web data, user-reported figures in public forums, and comparisons with published pricing from competitors.

1st Optimal Pricing History: What the Data Shows

Pricing for 1st Optimal's core protocols has evolved alongside broader market shifts in compounded hormone and peptide therapy costs. Based on publicly available and user-reported data collected between 2021 and early 2025, the following patterns emerge.

Testosterone Replacement Therapy Costs

Compounded testosterone cypionate injections represent the lowest-cost entry point. User-reported figures from Reddit's r/Testosterone and r/Hormones communities, cross-referenced with archived snapshots, suggest 1st Optimal's injectable TRT protocols were priced in the $150, $220 per month range in 2022 to 2023, inclusive of medication but excluding initial lab work.

For context, the American Urological Association's 2018 testosterone deficiency guideline (updated 2022) identifies testosterone cypionate as a first-line therapy [2], and the wholesale acquisition cost of 200 mg/mL testosterone cypionate 10 mL vials through standard pharmacy channels runs roughly $30, $60. The markup to approximately $150, $220 per month reflects compounding fees, provider overhead, and platform margin.

Peptide Protocol Pricing

Peptide therapies, including growth hormone secretagogues such as sermorelin, ipamorelin, and CJC-1295, carry higher price points. User-reported costs for combined ipamorelin/CJC-1295 protocols at 1st Optimal ranged from $250 to $350 per month as of late 2023.

The FDA has flagged several peptides as not meeting the criteria for compounding under section 503A. In 2023, the agency placed BPC-157 on its list of drugs that raise serious safety concerns and may not be compounded. [3] Clinics continuing to offer such peptides after FDA advisories carry regulatory and patient-safety risk that prospective patients should weigh.

GLP-1 and Semaglutide Pricing

Compounded semaglutide entered the 1st Optimal catalog during the 2022 to 2023 shortage period, consistent with industry-wide expansion. Industry pricing for compounded semaglutide ranged from $199 to $499 per month across direct-to-consumer platforms during 2023. [4]

The FDA declared the shortage of semaglutide injection resolved for all dosage forms as of February 2024, which changes the legal basis for compounding under 503A/503B. [5] Clinics that continue offering compounded semaglutide post-shortage resolution may be doing so outside FDA guidance. Patients considering this option should ask the prescribing physician directly about the pharmacy's 503B status and the current FDA shortage designation.

Price Trajectory: 2021 to 2025

The following trajectory framework synthesizes publicly available pricing signals for 1st Optimal alongside industry benchmarks:

| Period | Estimated TRT Monthly Cost | Estimated Peptide Monthly Cost | Key Market Driver | |---|---|---|---| | 2021 | $120, $160 | $180, $250 | Post-COVID telehealth expansion | | 2022 | $150, $200 | $220, $300 | Compounding demand surge | | 2023 | $160, $220 | $250, $350 | GLP-1 shortage; regulatory scrutiny | | Early 2025 | $180, $260 (est.) | $270, $400 (est.) | FDA enforcement; supply chain costs |

These ranges are estimates based on user-reported data and competitor published pricing. They have not been independently confirmed by 1st Optimal. Actual current pricing requires direct inquiry with the clinic.

Is 1st Optimal Legit? How to Evaluate Any Concierge Hormone Clinic

The question of legitimacy for a cash-pay telehealth brand involves multiple independent verification layers. No single data source is sufficient.

Physician Licensing and State Medical Board Records

Every physician prescribing through a telehealth platform must hold a valid license in the patient's state. State medical board records are publicly searchable. For example, the Texas Medical Board's license lookup [6] and the California Medical Board's BreEZe system both provide real-time license status and any disciplinary actions.

Before enrolling with 1st Optimal or any similar brand, search the prescribing physician's name in your state's medical board database. A clean license record does not guarantee quality of care, but a history of disciplinary actions is a significant warning sign.

Pharmacy Accreditation: PCAB and 503B Status

Compounding pharmacies used by telehealth clinics should hold either PCAB (Pharmacy Compounding Accreditation Board) accreditation or operate as FDA-registered 503B outsourcing facilities. The FDA publishes a current list of registered 503B outsourcing facilities. [7]

1st Optimal does not publicly name its compounding pharmacy partners as of January 2025. Patients should ask directly which pharmacy fulfills their prescription and verify that pharmacy's accreditation before accepting the first shipment.

LegitScript Verification

LegitScript is a third-party certification body that verifies online pharmacies and telehealth platforms against federal and state law. As of January 2025, 1st Optimal does not appear in LegitScript's verified merchant database. The absence of LegitScript certification is not automatically disqualifying, because certification is voluntary, but it means no independent third party has audited the platform's prescribing and dispensing practices. [8]

BBB Complaint History

The Better Business Bureau records consumer complaints and assigns accreditation status. As of January 2025, 1st Optimal does not hold BBB accreditation. Searching the BBB national database for the brand name may surface filed complaints, though coverage is incomplete because complaint filing is voluntary. [9]

Regulatory Environment Affecting 1st Optimal's Protocol Offerings

Understanding the regulatory context is necessary to assess both the safety and the durability of any clinic's peptide or compounded hormone offerings.

FDA Oversight of Compounded Testosterone

The FDA classifies testosterone as a Schedule III controlled substance under the Controlled Substances Act. [10] Compounded testosterone is legal under 503A when prepared by a licensed pharmacist based on a valid patient-specific prescription. The agency has issued warning letters to compounding pharmacies producing testosterone without adequate quality controls. Patients should verify their pharmacy holds valid DEA registration for Schedule III compounds.

The FDA's Evolving Peptide Policy

The FDA's position on compounded peptides has tightened materially since 2021. The agency's Interim Policy on Compounding of Certain Bulk Drug Substances identifies specific peptides that may not be compounded. [11] Sermorelin retains a more favorable regulatory status than BPC-157 or TB-500, but the field continues to shift. Clinics offering broad peptide menus without transparently communicating current FDA status to patients are not meeting a basic standard of informed consent.

The Endocrine Society's 2020 clinical practice guideline on growth hormone deficiency in adults states that "growth hormone therapy should be prescribed only when biochemical GH deficiency has been confirmed," [12] a standard that many direct-to-consumer peptide protocols do not meet because they do not require provocative testing.

Semaglutide Compounding After Shortage Resolution

Following the FDA's February 2024 announcement that the semaglutide shortage was resolved [5], 503A pharmacies lost the legal basis for compounding semaglutide copies. The FDA issued a compliance policy in May 2024 giving clinics a wind-down period. Prescribing compounded semaglutide after that window closes exposes both the clinic and the patient to legal risk. Patients currently receiving compounded semaglutide from any platform, including 1st Optimal, should ask their provider for the current FDA status and a documented clinical justification.

How 1st Optimal Pricing Compares to Competitors

Placing 1st Optimal's pricing in context requires comparing it against published or reliably reported competitor pricing for similar protocols.

TRT-Focused Competitors

Defy Medical (Tampa, FL) publishes starting TRT costs of approximately $175, $250 per month for injectable testosterone cypionate protocols, inclusive of physician management fees. [13] Marek Health, another performance-focused concierge brand, has reported similar ranges. Hone Health's published pricing for testosterone therapy starts at $75 for initial evaluation, with ongoing medication costs varying by protocol.

1st Optimal's estimated $180, $260 per month for TRT as of early 2025 places it at the upper-middle tier of this market.

Peptide Protocol Competitors

Peptide-inclusive programs across the market typically run $300, $550 per month when combining a growth hormone secretagogue with TRT. 1st Optimal's estimated $270, $400 for peptide protocols alone positions it competitively, provided the quality of clinical oversight and pharmacy sourcing is equivalent. That "provided" is doing significant work in that sentence. Without published pharmacy partners and accreditation data, the value comparison is incomplete.

What Drives Premium Pricing in This Category

Three factors tend to justify above-median pricing in cash-pay hormone clinics: physician specialization (board certification in endocrinology or urology), in-house or PCAB-accredited pharmacy relationships, and comprehensive lab monitoring included in the monthly fee. Patients paying premium prices should verify all three with the clinic before committing.

The American Association of Clinical Endocrinology's 2022 clinical practice guideline on hypogonadism recommends testosterone therapy only after two morning testosterone measurements confirm deficiency, and specifies monitoring at 3 and 6 months after initiation. [14] Clinics charging premium fees that do not include this monitoring cadence are not delivering care consistent with specialty guidelines.

Red Flags and Green Flags When Evaluating 1st Optimal

Not every concern about a clinic is disqualifying, but certain patterns warrant extra scrutiny.

Red Flags to Investigate

Absence of named pharmacy partners is a red flag. So is the offer of peptides that the FDA has placed on its bulk drug substances of concern list, without documented clinical rationale. Pricing that changes significantly between initial consultation and first invoice is a pattern documented in BBB complaints across the cash-pay telehealth sector generally. [9]

Prescriptions issued without lab-confirmed hormone deficiency are inconsistent with AUA [2] and AACE [14] guidelines. Any clinic that issues TRT prescriptions after a brief symptom questionnaire alone should prompt a second opinion.

Green Flags Worth Confirming

A green flag is a named, verifiable compounding pharmacy with published PCAB or 503B status. Physicians with board certification in endocrinology, urology, or internal medicine, verifiable through the American Board of Medical Specialties, indicate appropriate clinical training. Transparent, itemized fee schedules and written informed consent documents covering regulatory status of compounded drugs are consistent with responsible practice.

What Patients Commonly Report About 1st Optimal

Public complaint and review data for 1st Optimal is sparse relative to larger competitors, which itself reflects the brand's smaller footprint rather than necessarily a cleaner complaint record.

Positive Feedback Patterns

Positive user reports across Reddit communities and Trustpilot-adjacent platforms cluster around responsive provider communication, personalized protocol design, and willingness to adjust dosing based on follow-up labs. These are consistent with the concierge model's value proposition.

Complaint Patterns

Negative reports center on pricing opacity during the onboarding process and delays in prescription fulfillment after payment. These are not unique to 1st Optimal: a 2023 analysis of telehealth platform complaints filed with state attorneys general found that billing disputes and prescription delays were the two most common complaint categories across direct-to-consumer health platforms generally. [15]

Patients who experience billing disputes with any telehealth provider can file complaints with their state attorney general's consumer protection office, the FTC at ReportFraud.ftc.gov, and the FDA's MedWatch program for medication quality issues. [16]

Clinical Standards Any Hormone Clinic Should Meet

Regardless of pricing tier, certain clinical standards apply to any responsible TRT or hormone therapy program.

Pre-Treatment Workup

The Endocrine Society's 2018 clinical practice guideline on testosterone therapy in men with hypogonadism specifies that diagnosis requires "unequivocally and consistently low serum testosterone concentrations," confirmed on at least two separate morning measurements, along with signs and symptoms of deficiency. [17] A comprehensive metabolic panel, CBC, PSA (in men over 40), and hematocrit are standard pre-treatment labs.

Monitoring During Treatment

After TRT initiation, testosterone levels should be measured at 3 months and 6 months, with hematocrit checked at the same intervals. The 2018 Endocrine Society guideline specifies withholding therapy if hematocrit exceeds 54%. [17] Clinics that do not include monitoring labs in their pricing structure, or that charge separately per draw without clear disclosure, increase the total cost of care beyond the advertised monthly rate.

Informed Consent for Compounded Drugs

Patients receiving compounded medications must be informed that these products are not FDA-approved, have not undergone the agency's efficacy review, and may differ in potency from lot to lot. This disclosure is a legal requirement under 21 U.S.C. § 353b [1] and an ethical requirement under any standard of medical practice.